Modified-Release Methylphenidate Coating for Delayed Sustained Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methylphenidate formulations for treating ADHD have short half-lives, require multiple daily doses, cause compliance issues, and are prone to substance abuse due to euphoric effects, with existing sustained-release forms being complex and costly.
Innovation Solution
Developed modified release formulations comprising a core containing CNS stimulants, a sustained release layer using water-insoluble polymers, and a delayed release layer to provide controlled drug delivery once daily, avoiding premature release and minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immediate-release methylphenidate formulations are used, then the drug is well absorbed and effective, but the half-life is extremely short requiring multi-dose treatment and causing compliance issues
Solution Approach 1:
The formulation segments the drug release process into two distinct phases: an initial lag period (0-4 hours) where drug release is suppressed, followed by a sustained release phase (4-24 hours) where drug is released at a controlled rate. This segmentation resolves the contradiction by maintaining short-term containment while enabling long-term delivery.
Solution Approach 2:
The formulation performs preliminary action by establishing a lag period before drug release begins. This preliminary phase prepares the system for sustained release, allowing the drug to be delivered over an extended period while maintaining therapeutic effectiveness and improving compliance.
2Reliability
If high doses of methylphenidate are administered to achieve effective concentration, then therapeutic effect is improved, but side effects such as anorexia, weight loss, and dizziness increase
Solution Approach 1:
The formulation changes the temporal parameters of drug delivery by introducing a lag period and extending the release duration. This transforms the concentration-time profile from a sharp peak to a prolonged plateau, maintaining therapeutic effectiveness while reducing the magnitude of Cmax and associated side effects.
Solution Approach 2:
The formulation dynamically adjusts the drug release rate through two phases: initially suppressing release during the lag period, then transitioning to a controlled sustained release phase. This dynamic control optimizes the balance between therapeutic effect and side effect minimization.
3Ease of operation
If sustained-release formulations are used to extend drug delivery, then patient compliance improves and dosing frequency decreases, but the formulations become complex and costly
Solution Approach 1:
The formulation uses segmentation to create a two-phase release system with distinct functional layers. This segmented approach achieves complex release kinetics (lag followed by sustained release) while maintaining relatively simple formulation components and manufacturing processes.
Solution Approach 2:
The formulation employs a nested structure where the drug-containing core is enclosed within a polymer coating layer. This nested design enables the lag-sustained release profile through the layered architecture, achieving extended delivery functionality with a relatively simple composite structure.
4Reliability
If methylphenidate is administered to treat ADHD symptoms, then cognitive function improves, but the drug produces euphoric effects when misused presenting high potential for substance abuse
Solution Approach 1:
The formulation changes the temporal parameters of drug delivery by extending the release duration and reducing the peak concentration. This parameter modification eliminates the rapid onset and intense peak associated with euphoric effects, while maintaining adequate therapeutic levels for cognitive improvement throughout the day.
Solution Approach 2:
The formulation dynamically controls drug release to provide steady therapeutic levels without sharp peaks. This dynamic release profile maintains cognitive benefits while minimizing the euphoric effects that drive abuse potential, as the drug is delivered gradually over 20 hours rather than all at once.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations maintain steady drug levels for extended periods, improving patient compliance and reducing adverse effects by delaying release for 4 to 12 hours, suitable for ADHD treatment in various populations.
Implementation Method 1
a sustained release layer using water-insoluble polymers
Implementation Method 2
delayed release layer to provide controlled drug delivery
Data Source
AI summary
The present invention relates to therapeutic compositions and methods for the treatment of attention deficit disorder (ADD), or attention deficit hyperactivity disorder (ADHD). The present invention more particularly relates to a modified-release pharmaceutical formulation designed to improve the delivery and efficacy of central nervous system (CNS) stimulants. The composition consists of a drug-containing core with a CNS stimulant and pharmaceutically acceptable excipients. This core is coated with a sustained-release (SR) layer comprising one or more polymers selected from water-insoluble and water-insoluble pH-dependent polymers, and one or more pharmaceutically acceptable excipients which regulates the gradual release of the drug. Surrounding the SR layer is a delayed-release (DR) outer layer that controls the onset of drug release. This approach aims to enhance symptom control, reduce dosing frequency, and improve patient compliance in the treatment of ADD and ADHD.